Dr David Charles Feist, DDS | |
80 B Veteran Blvd, Acoma-canoncito-laguna, Acomita, NM 87034 | |
(505) 552-5310 | |
Not Available |
Full Name | Dr David Charles Feist |
---|---|
Gender | Male |
Speciality | Dentist |
Location | 80 B Veteran Blvd, Acomita, New Mexico |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1598796856 | NPI | - | NPPES |
552788 | Medicaid | AZ | |
000B3765 | Medicaid | NM |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
122300000X | Dentist | DS0000007399 (Tennessee) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr David Charles Feist, DDS Po Box 130, San Fidel, NM 87049-0130 Ph: (505) 552-5310 | Dr David Charles Feist, DDS 80 B Veteran Blvd, Acoma-canoncito-laguna, Acomita, NM 87034 Ph: (505) 552-5310 |
News Archive
Newly published findings about the phylogenetics and systematics of some previously known, but also other yet to be identified species of Old World Leaf-nosed bats, provide the first contribution to a recently launched collection of research articles, whose task is to help scientists from across disciplines to better understand potential hosts and vectors of zoonotic diseases, such as the Coronavirus.
A new USC study suggests that certain neighborhoods - particularly those characterized by poverty and unemployment - may pose an environmental risk to the developing brains of children, impacting neurocognitive performance and even brain size.
Genentech, a member of the Roche Group, today announced that data showing new personalized approaches for people with skin and lung cancer, plus new data with Avastin in ovarian cancer, will be presented at the 47th Annual Meeting of the American Society of Clinical Oncology.
The U.S. Food and Drug Administration today granted accelerated approval for Keytruda (pembrolizumab) to treat patients with advanced (metastatic) non-small cell lung cancer (NSCLC) whose disease has progressed after other treatments and with tumors that express a protein called PD-L1. Keytruda is approved for use with a companion diagnostic, the PD-L1 IHC 22C3 pharmDx test, the first test designed to detect PD-L1 expression in non-small cell lung tumors.
Antigenics Inc. reported today its results for the quarter ended June 30, 2010.
› Verified 3 days ago